Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- StemRIM to Set Up Collaborative Lab in Osaka University
February 14, 2020
- Mitsubishi Chemical to Rev Up Next-Gen Therapy Biz to Enliven Pharma Unit: Chief
February 14, 2020
- Polatuzumab Vedotin Hits Main Goal in Japan PII for DLBCL: Chugai
February 14, 2020
- Ono Revamps Japan Sales Structure to Gear Up for New Launches
February 13, 2020
- Bayer’s Eylea Effective at Both 12-Week and 16-Week Intervals: PIV Study
February 13, 2020
- Astex’s Novel Cancer Drug Accepted for FDA Review: Otsuka
February 13, 2020
- Xtandi Extends Overall Survival in Non-Metastatic CRPC
February 13, 2020
- Followup Data Backs Padcev-Keytruda Combo for 1st Line Bladder Cancer: Astellas/Seattle Genetics
February 13, 2020
- In Japan Too, Pfizer and Mylan Prepping for Pending Viatris Integration
February 12, 2020
- With 2 New Deals Inked, Meiji Hunkering Down for Full-Scale Entry into Hematology Market
February 12, 2020
- Sumitomo Dainippon to Revise FY2022 Targets after Roivant Deal: President
February 10, 2020
- Chugai Joins NCC Scheme to Offer Free Drugs after Genomic Profiling
February 10, 2020
- After Erleada, Janssen Joins Hands with Nippon Shinyaku for Zytiga Too
February 10, 2020
- FDA Accepts Nippon Shinyaku’s DMD Drug for Review, Target Date Set for Q3 2020
February 10, 2020
- Stemirac Posts 130 Million Yen Sales in May-December: Nipro
February 10, 2020
- I’rom Teams Up with Shanghai Public Health Clinical Center to Tackle Novel Coronavirus
February 10, 2020
- Novo Nordisk’s Fiasp Ultra-Fast Acting Insulin Now Available in Japan
February 10, 2020
- Japan Ethical Drug Sales Up 3.7% in December 2019: Crecon
February 10, 2020
- With Orix Deal, Reborn Kobayashi Kako Aims to Become Follow-Up to Big 3 Generic Players
February 7, 2020
- Keytruda’s Global Sales Cross US$10 Billion Mark in 2019, Tops Opdivo’s Including Asia
February 7, 2020
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…